These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

742 related items for PubMed ID: 18550004

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Certolizumab pegol for the management of Crohn's disease in adults.
    Rivkin A.
    Clin Ther; 2009 Jun; 31(6):1158-76. PubMed ID: 19695385
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: results of the FACTS survey.
    Schoepfer AM, Vavricka SR, Binek J, Felley C, Geyer M, Manz M, Rogler G, de Saussure P, Sauter B, Seibold F, Straumann A, Michetti P, Swiss IBDnet.
    Inflamm Bowel Dis; 2010 Jun; 16(6):933-8. PubMed ID: 20014021
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease.
    Stidham RW, Lee TC, Higgins PD, Deshpande AR, Sussman DA, Singal AG, Elmunzer BJ, Saini SD, Vijan S, Waljee AK.
    Aliment Pharmacol Ther; 2014 Jun; 39(12):1349-62. PubMed ID: 24749763
    [Abstract] [Full Text] [Related]

  • 9. Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease.
    Smith LS, Nelson M, Dolder CR.
    Ann Pharmacother; 2010 Feb; 44(2):333-42. PubMed ID: 20118143
    [Abstract] [Full Text] [Related]

  • 10. Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease.
    Williams CJ, Peyrin-Biroulet L, Ford AC.
    Aliment Pharmacol Ther; 2014 Mar; 39(5):447-58. PubMed ID: 24444171
    [Abstract] [Full Text] [Related]

  • 11. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab.
    Sandborn WJ, Abreu MT, D'Haens G, Colombel JF, Vermeire S, Mitchev K, Jamoul C, Fedorak RN, Spehlmann ME, Wolf DC, Lee S, Rutgeerts P.
    Clin Gastroenterol Hepatol; 2010 Aug; 8(8):688-695.e2. PubMed ID: 20451663
    [Abstract] [Full Text] [Related]

  • 12. Is there a benefit from the concomitant use of immunosupression with anti-TNF in Crohn's disease; heads or tails?
    Lakatos PL.
    Rev Recent Clin Trials; 2009 Sep; 4(3):152-8. PubMed ID: 20028325
    [Abstract] [Full Text] [Related]

  • 13. Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials.
    Jones JL, Kaplan GG, Peyrin-Biroulet L, Baidoo L, Devlin S, Melmed GY, Tanyingoh D, Raffals L, Irving P, Kozuch P, Sparrow M, Velayos F, Bressler B, Cheifetz A, Colombel JF, Siegel CA.
    Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2233-40.e1-2; quiz e177-8. PubMed ID: 26142167
    [Abstract] [Full Text] [Related]

  • 14. Maintenance therapy with certolizumab pegol for Crohn's disease.
    Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OØ, Hanauer SB, McColm J, Bloomfield R, Sandborn WJ, PRECISE 2 Study Investigators.
    N Engl J Med; 2007 Jul 19; 357(3):239-50. PubMed ID: 17634459
    [Abstract] [Full Text] [Related]

  • 15. Optimizing anti-TNF treatment in inflammatory bowel disease.
    Rutgeerts P, Van Assche G, Vermeire S.
    Gastroenterology; 2004 May 19; 126(6):1593-610. PubMed ID: 15168370
    [Abstract] [Full Text] [Related]

  • 16. [Crohn's disease--infliximab, adalimumab and certolizumab-pegol: clinical value of anti-TNF-alpha treatment].
    Schreiber S.
    Dtsch Med Wochenschr; 2007 Aug 19; 132(34-35):1770-4. PubMed ID: 17713889
    [Abstract] [Full Text] [Related]

  • 17. Meta-analysis: the efficacy and safety of certolizumab pegol in Crohn's disease.
    Shao LM, Chen MY, Cai JT.
    Aliment Pharmacol Ther; 2009 Mar 15; 29(6):605-14. PubMed ID: 19183161
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.
    Dretzke J, Edlin R, Round J, Connock M, Hulme C, Czeczot J, Fry-Smith A, McCabe C, Meads C.
    Health Technol Assess; 2011 Feb 15; 15(6):1-244. PubMed ID: 21291629
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.